EXPERT REACTION: Novavax vaccine shows 89.3% efficacy in phase 3 trial
Not peer-reviewed: This work has not been scrutinised by independent experts, or the story does not contain research data to review (for example an opinion piece). If you are reporting on research that has yet to go through peer-review (eg. conference abstracts and preprints) be aware that the findings can change during the peer review process.
It has just been reported that the Novavax COVID-19 Vaccine has demonstrated an 89.3% efficacy in its UK phase 3 trial. Below, experts comment on the findings.
Organisation/s: Australian Science Media Centre, La Trobe University, The University of New South Wales
Funder: N/A
News for:
Australia
NSW
VIC
QLD
Media contact details for this story are only visible to registered journalists.
Expert Reaction
These comments have been collated by the Science Media Centre to provide a variety of expert perspectives on this issue. Feel free to use these quotes in your stories. Views expressed are the personal opinions of the experts named. They do not represent the views of the SMC or any other organisation unless specifically stated.